

# Global Liposomal-based Drug Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G902CE00C5C3EN.html>

Date: April 2026

Pages: 137

Price: US\$ 3,660.00 (Single User License)

ID: G902CE00C5C3EN

## Abstracts

The global Liposomal-based Drug market size is predicted to grow from US\$ 6466 million in 2025 to US\$ 12740 million in 2032; it is expected to grow at a CAGR of 10.4% from 2026 to 2032.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market's potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.

LPI (LP Information)' newest research report, the 'Liposomal-based Drug Industry Forecast' looks at past sales and reviews total world Liposomal-based Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Liposomal-based Drug sales for 2026 through 2032. With Liposomal-based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Liposomal-based Drug industry.

This Insight Report provides a comprehensive analysis of the global Liposomal-based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Liposomal-based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liposomal-based Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomal-based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomal-based Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal-based Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:

Liposomes Drugs

Lipid Nanoparticle Drugs

Segmentation by Application:

Hospital

Retail Pharmacy

Other

This report also splits the market by region:

#### Americas

United States

Canada

Mexico

Brazil

#### APAC

China

Japan

Korea

Southeast Asia

India

Australia

#### Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Liposomal-based Drug Market Size (2021-2032)
- 2.1.2 Liposomal-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Liposomal-based Drug by Country/Region (2021, 2025 & 2032)

#### 2.2 Liposomal-based Drug Segment by Type

- 2.2.1 Liposomes Drugs
- 2.2.2 Lipid Nanoparticle Drugs
- 2.2.3 Liposomal-based Drug Market Size by Type
  - 2.2.3.1 Liposomal-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
  - 2.2.3.2 Global Liposomal-based Drug Market Size Market Share by Type (2021-2026)

#### 2.3 Liposomal-based Drug Segment by Application

- 2.3.1 Hospital
- 2.3.2 Retail Pharmacy
- 2.3.3 Other
- 2.3.4 Liposomal-based Drug Market Size by Application
  - 2.3.4.1 Liposomal-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
  - 2.3.4.2 Global Liposomal-based Drug Market Size Market Share by Application (2021-2026)

### 3 LIPOSOMAL-BASED DRUG MARKET SIZE BY PLAYER

- 3.1 Liposomal-based Drug Market Size Market Share by Player
  - 3.1.1 Global Liposomal-based Drug Revenue by Player (2021-2026)
  - 3.1.2 Global Liposomal-based Drug Revenue Market Share by Player (2021-2026)
- 3.2 Global Liposomal-based Drug Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
  - 3.3.1 Competition Landscape Analysis
  - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

## **4 LIPOSOMAL-BASED DRUG BY REGION**

- 4.1 Liposomal-based Drug Market Size by Region (2021-2026)
- 4.2 Global Liposomal-based Drug Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Liposomal-based Drug Market Size Growth (2021-2026)
- 4.4 APAC Liposomal-based Drug Market Size Growth (2021-2026)
- 4.5 Europe Liposomal-based Drug Market Size Growth (2021-2026)
- 4.6 Middle East & Africa Liposomal-based Drug Market Size Growth (2021-2026)

## **5 AMERICAS**

- 5.1 Americas Liposomal-based Drug Market Size by Country (2021-2026)
- 5.2 Americas Liposomal-based Drug Market Size by Type (2021-2026)
- 5.3 Americas Liposomal-based Drug Market Size by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

## **6 APAC**

- 6.1 APAC Liposomal-based Drug Market Size by Region (2021-2026)
- 6.2 APAC Liposomal-based Drug Market Size by Type (2021-2026)
- 6.3 APAC Liposomal-based Drug Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India

## 6.9 Australia

## **7 EUROPE**

### 7.1 Europe Liposomal-based Drug Market Size by Country (2021-2026)

### 7.2 Europe Liposomal-based Drug Market Size by Type (2021-2026)

### 7.3 Europe Liposomal-based Drug Market Size by Application (2021-2026)

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

### 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

### 8.1 Middle East & Africa Liposomal-based Drug by Region (2021-2026)

### 8.2 Middle East & Africa Liposomal-based Drug Market Size by Type (2021-2026)

### 8.3 Middle East & Africa Liposomal-based Drug Market Size by Application (2021-2026)

### 8.4 Egypt

### 8.5 South Africa

### 8.6 Israel

### 8.7 Turkey

### 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

### 9.1 Market Drivers & Growth Opportunities

### 9.2 Market Challenges & Risks

### 9.3 Industry Trends

## **10 GLOBAL LIPOSOMAL-BASED DRUG MARKET FORECAST**

### 10.1 Global Liposomal-based Drug Forecast by Region (2027-2032)

#### 10.1.1 Global Liposomal-based Drug Forecast by Region (2027-2032)

#### 10.1.2 Americas Liposomal-based Drug Forecast

#### 10.1.3 APAC Liposomal-based Drug Forecast

#### 10.1.4 Europe Liposomal-based Drug Forecast

#### 10.1.5 Middle East & Africa Liposomal-based Drug Forecast

### 10.2 Americas Liposomal-based Drug Forecast by Country (2027-2032)

- 10.2.1 United States Market Liposomal-based Drug Forecast
- 10.2.2 Canada Market Liposomal-based Drug Forecast
- 10.2.3 Mexico Market Liposomal-based Drug Forecast
- 10.2.4 Brazil Market Liposomal-based Drug Forecast
- 10.3 APAC Liposomal-based Drug Forecast by Region (2027-2032)
  - 10.3.1 China Liposomal-based Drug Market Forecast
  - 10.3.2 Japan Market Liposomal-based Drug Forecast
  - 10.3.3 Korea Market Liposomal-based Drug Forecast
  - 10.3.4 Southeast Asia Market Liposomal-based Drug Forecast
  - 10.3.5 India Market Liposomal-based Drug Forecast
  - 10.3.6 Australia Market Liposomal-based Drug Forecast
- 10.4 Europe Liposomal-based Drug Forecast by Country (2027-2032)
  - 10.4.1 Germany Market Liposomal-based Drug Forecast
  - 10.4.2 France Market Liposomal-based Drug Forecast
  - 10.4.3 UK Market Liposomal-based Drug Forecast
  - 10.4.4 Italy Market Liposomal-based Drug Forecast
  - 10.4.5 Russia Market Liposomal-based Drug Forecast
- 10.5 Middle East & Africa Liposomal-based Drug Forecast by Region (2027-2032)
  - 10.5.1 Egypt Market Liposomal-based Drug Forecast
  - 10.5.2 South Africa Market Liposomal-based Drug Forecast
  - 10.5.3 Israel Market Liposomal-based Drug Forecast
  - 10.5.4 Turkey Market Liposomal-based Drug Forecast
- 10.6 Global Liposomal-based Drug Forecast by Type (2027-2032)
- 10.7 Global Liposomal-based Drug Forecast by Application (2027-2032)
  - 10.7.1 GCC Countries Market Liposomal-based Drug Forecast

## **11 KEY PLAYERS ANALYSIS**

- 11.1 Johnson & Johnson
  - 11.1.1 Johnson & Johnson Company Information
  - 11.1.2 Johnson & Johnson Liposomal-based Drug Product Offered
  - 11.1.3 Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.1.4 Johnson & Johnson Main Business Overview
  - 11.1.5 Johnson & Johnson Latest Developments
- 11.2 Sun Pharmaceutical
  - 11.2.1 Sun Pharmaceutical Company Information
  - 11.2.2 Sun Pharmaceutical Liposomal-based Drug Product Offered
  - 11.2.3 Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and

## Market Share (2021-2026)

11.2.4 Sun Pharmaceutical Main Business Overview

11.2.5 Sun Pharmaceutical Latest Developments

## 11.3 CSPC

11.3.1 CSPC Company Information

11.3.2 CSPC Liposomal-based Drug Product Offered

11.3.3 CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 CSPC Main Business Overview

11.3.5 CSPC Latest Developments

## 11.4 Kinyond

11.4.1 Kinyond Company Information

11.4.2 Kinyond Liposomal-based Drug Product Offered

11.4.3 Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 Kinyond Main Business Overview

11.4.5 Kinyond Latest Developments

## 11.5 Teva

11.5.1 Teva Company Information

11.5.2 Teva Liposomal-based Drug Product Offered

11.5.3 Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Teva Main Business Overview

11.5.5 Teva Latest Developments

## 11.6 Fudan-Zhangjiang

11.6.1 Fudan-Zhangjiang Company Information

11.6.2 Fudan-Zhangjiang Liposomal-based Drug Product Offered

11.6.3 Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 Fudan-Zhangjiang Main Business Overview

11.6.5 Fudan-Zhangjiang Latest Developments

## 11.7 Zydus Cadila

11.7.1 Zydus Cadila Company Information

11.7.2 Zydus Cadila Liposomal-based Drug Product Offered

11.7.3 Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 Zydus Cadila Main Business Overview

11.7.5 Zydus Cadila Latest Developments

## 11.8 TTY Biopharma

- 11.8.1 TTY Biopharma Company Information
- 11.8.2 TTY Biopharma Liposomal-based Drug Product Offered
- 11.8.3 TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
- 11.8.4 TTY Biopharma Main Business Overview
- 11.8.5 TTY Biopharma Latest Developments
- 11.9 Pacira
  - 11.9.1 Pacira Company Information
  - 11.9.2 Pacira Liposomal-based Drug Product Offered
  - 11.9.3 Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.9.4 Pacira Main Business Overview
  - 11.9.5 Pacira Latest Developments
- 11.10 Luye Pharma
  - 11.10.1 Luye Pharma Company Information
  - 11.10.2 Luye Pharma Liposomal-based Drug Product Offered
  - 11.10.3 Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.10.4 Luye Pharma Main Business Overview
  - 11.10.5 Luye Pharma Latest Developments
- 11.11 Leadiant Biosciences
  - 11.11.1 Leadiant Biosciences Company Information
  - 11.11.2 Leadiant Biosciences Liposomal-based Drug Product Offered
  - 11.11.3 Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.11.4 Leadiant Biosciences Main Business Overview
  - 11.11.5 Leadiant Biosciences Latest Developments
- 11.12 Ipsen
  - 11.12.1 Ipsen Company Information
  - 11.12.2 Ipsen Liposomal-based Drug Product Offered
  - 11.12.3 Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.12.4 Ipsen Main Business Overview
  - 11.12.5 Ipsen Latest Developments
- 11.13 Sayre Therapeutics
  - 11.13.1 Sayre Therapeutics Company Information
  - 11.13.2 Sayre Therapeutics Liposomal-based Drug Product Offered
  - 11.13.3 Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)

- 11.13.4 Sayre Therapeutics Main Business Overview
- 11.13.5 Sayre Therapeutics Latest Developments
- 11.14 Jazz
  - 11.14.1 Jazz Company Information
  - 11.14.2 Jazz Liposomal-based Drug Product Offered
  - 11.14.3 Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.14.4 Jazz Main Business Overview
  - 11.14.5 Jazz Latest Developments
- 11.15 Alnylam
  - 11.15.1 Alnylam Company Information
  - 11.15.2 Alnylam Liposomal-based Drug Product Offered
  - 11.15.3 Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.15.4 Alnylam Main Business Overview
  - 11.15.5 Alnylam Latest Developments
- 11.16 Bausch Health
  - 11.16.1 Bausch Health Company Information
  - 11.16.2 Bausch Health Liposomal-based Drug Product Offered
  - 11.16.3 Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.16.4 Bausch Health Main Business Overview
  - 11.16.5 Bausch Health Latest Developments
- 11.17 Acrotech Biopharma
  - 11.17.1 Acrotech Biopharma Company Information
  - 11.17.2 Acrotech Biopharma Liposomal-based Drug Product Offered
  - 11.17.3 Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.17.4 Acrotech Biopharma Main Business Overview
  - 11.17.5 Acrotech Biopharma Latest Developments
- 11.18 Takeda
  - 11.18.1 Takeda Company Information
  - 11.18.2 Takeda Liposomal-based Drug Product Offered
  - 11.18.3 Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.18.4 Takeda Main Business Overview
  - 11.18.5 Takeda Latest Developments
- 11.19 Chiesi Farmaceutici
  - 11.19.1 Chiesi Farmaceutici Company Information

- 11.19.2 Chiesi Farmaceutici Liposomal-based Drug Product Offered
- 11.19.3 Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
- 11.19.4 Chiesi Farmaceutici Main Business Overview
- 11.19.5 Chiesi Farmaceutici Latest Developments
- 11.20 Gilead Sciences
  - 11.20.1 Gilead Sciences Company Information
  - 11.20.2 Gilead Sciences Liposomal-based Drug Product Offered
  - 11.20.3 Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  - 11.20.4 Gilead Sciences Main Business Overview
  - 11.20.5 Gilead Sciences Latest Developments

## **12 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Liposomal-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Liposomal-based Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Liposomes Drugs

Table 4. Major Players of Lipid Nanoparticle Drugs

Table 5. Liposomal-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 6. Global Liposomal-based Drug Market Size by Type (2021-2026) & (\$ millions)

Table 7. Global Liposomal-based Drug Market Size Market Share by Type (2021-2026)

Table 8. Liposomal-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 9. Global Liposomal-based Drug Market Size by Application (2021-2026) & (\$ millions)

Table 10. Global Liposomal-based Drug Market Size Market Share by Application (2021-2026)

Table 11. Global Liposomal-based Drug Revenue by Player (2021-2026) & (\$ millions)

Table 12. Global Liposomal-based Drug Revenue Market Share by Player (2021-2026)

Table 13. Liposomal-based Drug Key Players Head office and Products Offered

Table 14. Liposomal-based Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Liposomal-based Drug Market Size by Region (2021-2026) & (\$ millions)

Table 18. Global Liposomal-based Drug Market Size Market Share by Region (2021-2026)

Table 19. Global Liposomal-based Drug Revenue by Country/Region (2021-2026) & (\$ millions)

Table 20. Global Liposomal-based Drug Revenue Market Share by Country/Region (2021-2026)

Table 21. Americas Liposomal-based Drug Market Size by Country (2021-2026) & (\$ millions)

Table 22. Americas Liposomal-based Drug Market Size Market Share by Country (2021-2026)

Table 23. Americas Liposomal-based Drug Market Size by Type (2021-2026) & (\$ millions)

Table 24. Americas Liposomal-based Drug Market Size Market Share by Type (2021-2026)

Table 25. Americas Liposomal-based Drug Market Size by Application (2021-2026) & (\$ millions)

Table 26. Americas Liposomal-based Drug Market Size Market Share by Application (2021-2026)

Table 27. APAC Liposomal-based Drug Market Size by Region (2021-2026) & (\$ millions)

Table 28. APAC Liposomal-based Drug Market Size Market Share by Region (2021-2026)

Table 29. APAC Liposomal-based Drug Market Size by Type (2021-2026) & (\$ millions)

Table 30. APAC Liposomal-based Drug Market Size by Application (2021-2026) & (\$ millions)

Table 31. Europe Liposomal-based Drug Market Size by Country (2021-2026) & (\$ millions)

Table 32. Europe Liposomal-based Drug Market Size Market Share by Country (2021-2026)

Table 33. Europe Liposomal-based Drug Market Size by Type (2021-2026) & (\$ millions)

Table 34. Europe Liposomal-based Drug Market Size by Application (2021-2026) & (\$ millions)

Table 35. Middle East & Africa Liposomal-based Drug Market Size by Region (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Liposomal-based Drug Market Size by Type (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Liposomal-based Drug Market Size by Application (2021-2026) & (\$ millions)

Table 38. Key Market Drivers & Growth Opportunities of Liposomal-based Drug

Table 39. Key Market Challenges & Risks of Liposomal-based Drug

Table 40. Key Industry Trends of Liposomal-based Drug

Table 41. Global Liposomal-based Drug Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 42. Global Liposomal-based Drug Market Size Market Share Forecast by Region (2027-2032)

Table 43. Global Liposomal-based Drug Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 44. Global Liposomal-based Drug Market Size Forecast by Application

(2027-2032) & (\$ millions)

Table 45. Johnson & Johnson Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 46. Johnson & Johnson Liposomal-based Drug Product Offered

Table 47. Johnson & Johnson Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 48. Johnson & Johnson Main Business

Table 49. Johnson & Johnson Latest Developments

Table 50. Sun Pharmaceutical Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 51. Sun Pharmaceutical Liposomal-based Drug Product Offered

Table 52. Sun Pharmaceutical Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 53. Sun Pharmaceutical Main Business

Table 54. Sun Pharmaceutical Latest Developments

Table 55. CSPC Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 56. CSPC Liposomal-based Drug Product Offered

Table 57. CSPC Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 58. CSPC Main Business

Table 59. CSPC Latest Developments

Table 60. Kinyond Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 61. Kinyond Liposomal-based Drug Product Offered

Table 62. Kinyond Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 63. Kinyond Main Business

Table 64. Kinyond Latest Developments

Table 65. Teva Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 66. Teva Liposomal-based Drug Product Offered

Table 67. Teva Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 68. Teva Main Business

Table 69. Teva Latest Developments

Table 70. Fudan-Zhangjiang Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 71. Fudan-Zhangjiang Liposomal-based Drug Product Offered

Table 72. Fudan-Zhangjiang Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 73. Fudan-Zhangjiang Main Business

Table 74. Fudan-Zhangjiang Latest Developments

Table 75. Zydus Cadila Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 76. Zydus Cadila Liposomal-based Drug Product Offered

Table 77. Zydus Cadila Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 78. Zydus Cadila Main Business

Table 79. Zydus Cadila Latest Developments

Table 80. TTY Biopharma Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 81. TTY Biopharma Liposomal-based Drug Product Offered

Table 82. TTY Biopharma Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 83. TTY Biopharma Main Business

Table 84. TTY Biopharma Latest Developments

Table 85. Pacira Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 86. Pacira Liposomal-based Drug Product Offered

Table 87. Pacira Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 88. Pacira Main Business

Table 89. Pacira Latest Developments

Table 90. Luye Pharma Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 91. Luye Pharma Liposomal-based Drug Product Offered

Table 92. Luye Pharma Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 93. Luye Pharma Main Business

Table 94. Luye Pharma Latest Developments

Table 95. Leadiant Biosciences Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 96. Leadiant Biosciences Liposomal-based Drug Product Offered

Table 97. Leadiant Biosciences Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 98. Leadiant Biosciences Main Business

Table 99. Leadiant Biosciences Latest Developments

Table 100. Ipsen Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 101. Ipsen Liposomal-based Drug Product Offered

Table 102. Ipsen Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 103. Ipsen Main Business

Table 104. Ipsen Latest Developments

Table 105. Sayre Therapeutics Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 106. Sayre Therapeutics Liposomal-based Drug Product Offered

Table 107. Sayre Therapeutics Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 108. Sayre Therapeutics Main Business

Table 109. Sayre Therapeutics Latest Developments

Table 110. Jazz Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 111. Jazz Liposomal-based Drug Product Offered

Table 112. Jazz Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 113. Jazz Main Business

Table 114. Jazz Latest Developments

Table 115. Alnylam Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 116. Alnylam Liposomal-based Drug Product Offered

Table 117. Alnylam Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 118. Alnylam Main Business

Table 119. Alnylam Latest Developments

Table 120. Bausch Health Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 121. Bausch Health Liposomal-based Drug Product Offered

Table 122. Bausch Health Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 123. Bausch Health Main Business

Table 124. Bausch Health Latest Developments

Table 125. Acrotech Biopharma Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 126. Acrotech Biopharma Liposomal-based Drug Product Offered

Table 127. Acrotech Biopharma Liposomal-based Drug Revenue (\$ million), Gross

## Margin and Market Share (2021-2026)

Table 128. Acrotech Biopharma Main Business

Table 129. Acrotech Biopharma Latest Developments

Table 130. Takeda Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 131. Takeda Liposomal-based Drug Product Offered

Table 132. Takeda Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 133. Takeda Main Business

Table 134. Takeda Latest Developments

Table 135. Chiesi Farmaceutici Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 136. Chiesi Farmaceutici Liposomal-based Drug Product Offered

Table 137. Chiesi Farmaceutici Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 138. Chiesi Farmaceutici Main Business

Table 139. Chiesi Farmaceutici Latest Developments

Table 140. Gilead Sciences Details, Company Type, Liposomal-based Drug Area Served and Its Competitors

Table 141. Gilead Sciences Liposomal-based Drug Product Offered

Table 142. Gilead Sciences Liposomal-based Drug Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 143. Gilead Sciences Main Business

Table 144. Gilead Sciences Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Liposomal-based Drug Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Liposomal-based Drug Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Liposomal-based Drug Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Liposomal-based Drug Sales Market Share by Country/Region (2025)

Figure 8. Liposomal-based Drug Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Liposomal-based Drug Market Size Market Share by Type in 2025

Figure 10. Liposomal-based Drug in Hospital

Figure 11. Global Liposomal-based Drug Market: Hospital (2021-2026) & (\$ millions)

Figure 12. Liposomal-based Drug in Retail Pharmacy

Figure 13. Global Liposomal-based Drug Market: Retail Pharmacy (2021-2026) & (\$ millions)

Figure 14. Liposomal-based Drug in Other

Figure 15. Global Liposomal-based Drug Market: Other (2021-2026) & (\$ millions)

Figure 16. Global Liposomal-based Drug Market Size Market Share by Application in 2025

Figure 17. Global Liposomal-based Drug Revenue Market Share by Player in 2025

Figure 18. Global Liposomal-based Drug Market Size Market Share by Region (2021-2026)

Figure 19. Americas Liposomal-based Drug Market Size 2021-2026 (\$ millions)

Figure 20. APAC Liposomal-based Drug Market Size 2021-2026 (\$ millions)

Figure 21. Europe Liposomal-based Drug Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Liposomal-based Drug Market Size 2021-2026 (\$ millions)

Figure 23. Americas Liposomal-based Drug Value Market Share by Country in 2025

Figure 24. United States Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Liposomal-based Drug Market Size Market Share by Region in 2025

Figure 29. APAC Liposomal-based Drug Market Size Market Share by Type (2021-2026)

Figure 30. APAC Liposomal-based Drug Market Size Market Share by Application (2021-2026)

Figure 31. China Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Liposomal-based Drug Market Size Market Share by Country in 2025

Figure 38. Europe Liposomal-based Drug Market Size Market Share by Type (2021-2026)

Figure 39. Europe Liposomal-based Drug Market Size Market Share by Application (2021-2026)

Figure 40. Germany Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 42. UK Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Liposomal-based Drug Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Liposomal-based Drug Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Liposomal-based Drug Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Liposomal-based Drug Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 54. APAC Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 55. Europe Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 57. United States Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 58. Canada Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 61. China Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 62. Japan Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 63. Korea Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 65. India Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 66. Australia Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 67. Germany Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 68. France Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 69. UK Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 70. Italy Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 71. Russia Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 74. Israel Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Liposomal-based Drug Market Size 2027-2032 (\$ millions)

Figure 76. Global Liposomal-based Drug Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Liposomal-based Drug Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Liposomal-based Drug Market Size 2027-2032 (\$ millions)

## I would like to order

Product name: Global Liposomal-based Drug Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G902CE00C5C3EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G902CE00C5C3EN.html>